Lucid Diagnostics to Hold Fourth Quarter and Full Year 2025 Business Update Conference Call and Webcast on March 26, 2026
Lucid Diagnostics (Nasdaq: LUCD) will host a fourth quarter and full year 2025 business update conference call and webcast on March 26, 2026 at 8:30 AM ET.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Lucid Diagnostics (Nasdaq: LUCD) will host a fourth quarter and full year 2025 business update conference call and webcast on March 26, 2026 at 8:30 AM ET. The call will feature CEO Lishan Aklog and CFO Dennis McGrath discussing operations and Q4 2025 financial results.
The webcast and 30-day replay will be available in the investor relations section at luciddx.com; dial-in numbers are provided for U.S. and international callers.
Details
News Market Reaction – LUCD
On Mar 12, the day this news came out, LUCD closed 4.14% below the previous close.
Data tracked by StockTitan Argus for the Mar 12 session.
AI-generated analysis. How Rhea-AI works. Not financial advice.
Conference Call and Webcast at 8:30 AM ET
The webcast will be available at the investor relations section of the Company's website at luciddx.com. Alternatively, to access the conference call by telephone,
Following the conclusion of the conference call, a replay will be available for 30 days on the investor relations section of the Company's website at luciddx.com.
About Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage, cancer prevention medical diagnostics company, and subsidiary of PAVmed Inc. (Nasdaq: PAVM). Lucid is focused on the millions of patients with gastroesophageal reflux disease (GERD), also known as chronic heartburn, who are at risk of developing esophageal precancer and cancer. Lucid's EsoGuard® Esophageal DNA Test, performed on samples collected in a brief, noninvasive office procedure with its EsoCheck® Esophageal Cell Collection Device, represent the first and only commercially available tools designed with the goal of preventing cancer and cancer deaths through widespread, early detection of esophageal precancer in at-risk patients.
For more information, please visit www.luciddx.com and for more information about its parent company PAVmed, please visit www.pavmed.com.
View original content to download multimedia:https://www.prnewswire.com/news-releases/lucid-diagnostics-to-hold-fourth-quarter-and-full-year-2025-business-update-conference-call-and-webcast-on-march-26-2026-302710091.html
SOURCE Lucid Diagnostics
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.